Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aspen Pharmacare Holdings Ltd's Aspen Global Incorporated Announces Completion Of Acquisition Of Australian Product Portfolio From GlaxoSmithKline plc


Monday, 3 Dec 2012 01:00am EST 

Aspen Pharmacare Holdings Ltd announced with reference to the announcement made earlier regarding, Aspen Global Incorporated (Aspen Global), a wholly owned subsidiary of Aspen Holdings, had reached agreement with GlaxoSmithKline plc (GSK) for the acquisition of a portfolio of 25 established pharmaceutical products (the Products) distributed in Australia (the Transaction). The Transaction was subject to the following conditions precedent: The approval of the Australian competition authorities; and The approval of the Australian Foreign Investment Review Board. Aspen Holdings announced that both these conditions precedent have been met and that the Transaction has, as a result, been completed with effect from November 30, 2012. The final consideration in respect of the Transaction has reduced from GBP172.0 million to GBP 163.8 million. This reduction was due to the completion of the Transaction being subject to one of the pharmaceutical products originally included in the Transaction being excluded and the completion of the Transaction being delayed beyond October 31, 2012. 

Company Quote

1426.9
-10.0 -0.70%
3:51am EDT